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Abstract 
The aim of this research survey was to understand current global thinking around the need for and 
development of a paediatric biopharmaceutics classification system (pBCS) to be used for the 
development of paediatric medicines and regulatory purposes (e.g. Biowaivers). 
A literature review highlighted the paucity of data in this area and therefore a survey was developed 
to better understand this topic to identify areas of common thinking and highlight future research 
needs. 
Global experts in paediatric biopharmaceutics were identified from existing networks and public 
forums. An online survey was developed and circulated broadly to maximise participation. Sixty 
individuals (including academics, health care professionals, pharmaceutical industry scientists and 
regulators) completed the survey, bringing together their views on the need for a pBCS. 
The results highlighted that the area of greatest concern was the definition of BCS II and IV drugs 
within this population and additional research is required to generate evidence to underpin this 
issue. In questions relating to permeability and dissolution consensus was generally reached within 
the expert population suggesting that little additional research is required to define suitable criteria. 
More than 90% of those experts who participated agreed that a pBCS would be useful for paediatric 
populations with a greater need identified for the younger populations (newborn and infants 
compared to adolescents). 
The results presented will facilitate further discussion and research into the evidence to underpin a 
relevant pBCS. These results highlight the need for additional evidence and guidance in this area. 
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1. Introduction 
The biopharmaceutics classification system (BCS) was introduced in 1995 to facilitate the 
development of medicines for adults (Amidon et al., 1995). It has subsequently been used to justify 
the introduction of alternative formulations in the absence of a clinical study (EMA, 2010; FDA, 
1995). A BCS-based biowaiver has become an important and cost-saving tool in the development of 
new medicines and approval of generic medicines (FDA, 2000). 
The BCS is based on an understanding of the solubility and permeability of a drug and dissolution of 
the drug product. These key parameters can better assist in predicting the in vivo absorption of an 
oral medicine in adults. It is obvious that prediction of a drug’s absorption in a paediatric population 
offers significant benefits however the extrapolation of the adult BCS is not simple (Batchelor, 2014). 
There has been previous discussion on this topic yet there has been no effort in defining how the 
boundaries should be defined for paediatric populations (Abdel-Rahman et al., 2012; Batchelor, 
2014; Gandhi et al., 2014).  
This paper describes a survey of those working in paediatric biopharmaceutics used to identify 
current thinking and consensus in the area of paediatric biopharmaceutics specifically related to a 
paediatric biopharmaceutics classification system (pBCS). Parameters for the adult BCS were derived 
based on existing knowledge of a group of experts in the area (Amidon et al., 1995). The aim of this 
study was to derive parameters for a pBCS using a broad range of self-selecting experts. The Delphi 
technique is a widely used method for gathering data from respondents within their domain of 
expertise; this technique is designed to gain consensus on specific issues. In a Delphi process 
consensus is gained by a sequential series of questionnaires. This study aimed to gain insights and 
determine whether consensus exists in the definition and need for a pBCS and therefore a Delphi 
approach was taken although this was not followed by further questionnaires as this would be the 
role of the regulator and therefore the value of this follow-up was limited. 
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Previous literature reports have highlighted knowledge gaps in paediatric biopharmaceutics and this 
paper aims to address these gaps by: a) verification of the need for a pBCS; b) providing a view of 
trends and possible criteria to implement in a pBCS and c) obtaining a comprehensive list of further 
research required in the area of paediatric biopharmaceutics. 
2. Methods 
A literature review was used to aid in the design of the survey however only four papers were 
identified that referred to a paediatric biopharmaceutics classification system (Abdel-Rahman et al., 
2012; Batchelor, 2014; Gandhi et al., 2014; Shawahna, 2016). Key knowledge gaps in paediatric 
biopharmaceutics were identified by the European Paediatric Formulation Initiative (EuPFI, 
www.eupfi.org) biopharmaceutics workstream (a collaboration of academic and industrial 
pharmaceutical scientists working in paediatric medicines development) and these insights formed 
the basis of the survey. In line with the research objectives, a qualitative research approach was 
adopted. The questionnaire was constructed to minimise the burden to participants by presenting 
questions in a logical order with similar themes linked together. The respondents were given fixed 
options as well as allowed to input free text comments on each question to allow the best quality 
data to be generated whilst minimising the time burden to participants. A draft survey was reviewed 
collaboratively by the EuPFI biopharmaceutics workstream members to ensure that key questions 
were phrased unambiguously to maximise the value of the responses. It is acknowledged that pilot 
studies can improve the structure and clarity of questionnaires (Edwards, 2010), therefore, the 
survey was then tested online with some external experts from within the EuPFI wider network.  
Key areas of questioning identified included: 
 Is there a need for a pBCS, if so who should be involved in developing this? 
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 What are the relevant criteria to define high solubility, high permeability and rapid 
dissolution in paediatrics and are these values different within different age categories of 
paediatric populations? 
 What additional information is required to enable the development of a pBCS? 
Aspects of the Delphi process were considered within the design of the survey questions where 
consensus was sought from the respondents to identify areas of high agreement, such that these 
values can inform current thinking going forwards. Typical consensus levels used in Delphi 
approaches are 75% of participants agree on a parameter (Diamond et al., 2014). This approach was 
considered to be particularly relevant in defining the criteria used in solubility, permeability and 
dissolution parameters. 
There was a need to balance directed responses to ensure that the survey was simple and quick to 
complete yet also allow scope for participants to raise issues important to them. An increasing 
number of surveys in different fields are conducted using the internet, although it has some 
advantages (e.g. no or minimum cost, fast, reliable, easy to complete by the participants) and 
disadvantages (many people delete the online survey without opening it, for fear of spam or virus). 
Importantly, an online questionnaire maintains the anonymity of participants. The online survey 
software, Bristol Online Survey, (www.onlinesurveys.ac.uk ) was deemed most appropriate for this 
survey as it is specifically designed for academic research and public sector organisations and is fully 
compliant with UK data protection laws. 
For this survey, experts were identified on the basis of their recognised experience in the fields of 
formulation and paediatric biopharmaceutics. No geographical limitations were placed on the 
location of survey participants to best capture global expertise and practise. Experts were sought 
with the following backgrounds: 
 Academics (i.e. researchers, existing research networks and groups, scientific societies),  
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 Health care professionals (i.e. medical doctors, pharmacists, nurses and others working in a 
clinical environment) 
 Pharmaceutical Industry scientists (Small and Medium Enterprises (SME) and larger 
companies). 
 Regulators within agencies (at European and national level). 
The EuPFI was used as the primary network to distribute the survey via their membership. Additional 
experts outside of the EuPFI collaboration were targeted via direct mail from related and interested 
networks including: International Consortium for Innovation and Quality in Pharmaceutical 
Development (https://iqconsortium.org); Orbito (http://www.orbitoproject.eu/); APS 
Biopharmaceutics Focus Group (www.apsgb.co.uk)).  This approach to distribution of the survey was 
selected as an email from an existing contact is typically less likely to be deleted (Edwards, 2010). In 
addition a link to the survey was placed in relevant online networks (Linked In Groups including 
GastroPlusTM User Group; Regulatory Professionals in the development of paediatric formulations 
and AAPS Formulation Design and Development Section) with a request for anyone interested to 
complete the survey. This non-probability based convenience sampling method was selected and 
individuals were left with a choice to “opt in” to the questionnaire following an invitation via any of 
the methods outlined above. This self-selection was used as the population of interest is of a 
relatively small size and random sampling would be unlikely to provide sufficient results (Fricker, 
2012). The dissemination process followed would have attracted mainly European and US responses, 
however information on the geography of respondents was not collected. The survey included a 
question which enabled participants to provide details if they were willing to be contacted about 
their responses or for further details which would provide the research team with a sub-population 
to ask further questions if required.  
The survey was opened and advertised in September 2014 and responses collected until December 
2014. 
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3. Results and discussion 
3.1. Literature review 
The literature search revealed a total of four publications ((Abdel-Rahman et al., 2012; Batchelor, 
2014; Gandhi et al., 2014; Shawahna, 2016) ) discussing pBCS criteria. Dissolution parameters were 
not detailed in any of the publications. Permeability was aligned to adult values in three 
publications, using ClogP values (Batchelor, 2014; Shawahna, 2016) or based on absolute 
bioavailability in paediatrics where high permeability required an oral fraction dose absorbed of 90% 
or more compared to an intravenous study in paediatrics (Gandhi et al., 2014). According to the BCS, 
highly soluble drugs are those where the highest dose (or dose unit) is soluble in 250 mL aqueous 
liquid at a relevant pH range (Amidon et al., 1995). The relevant volume of liquid for different 
paediatric populations were discussed to the greatest extent within the four papers and a summary 
of the information contained within these papers is included in table 1. 
Table 1. Comparison of reported values for the volume in which the highest dose or dose unit should 
be soluble to classify a drug as highly soluble within a pBCS 
  Volume to use (mL) 
Reference Neonate (1 
month) 
Infant (12 
months) 
Child (3 
years) 
Child (10 
years) 
Adolescent (14 
years) 
(Abdel-
Rahman et al., 
2012) 
25 25 25 25 25 
(Batchelor, 
2014) 
13.2 37.7 56.6 111.4 188.7 
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 (2014) 
(Gandhi et al., 
2014) 
34.7 67.4 93.9 159.0 220.3 
(Shawahna, 
2016) 
14.9 38.9 54.0 121.0 192.0 
 
The justification for the 25 mL volume for all paediatric populations was not stated by Abdel Rahman 
et al (2012) (Abdel-Rahman et al., 2012).  Batchelor (2014) and Shawahna (2016) calculated a 
paediatric reference volume based on literature reports that the volume of gastric fluids in the 
fasted state in children is approximately 0.56 mL/kg (Crawford et al., 1990) relative to the adult 
gastric volume of 37.1 mL and BCS adult volume of 250mL; the slight differences reported relate to 
differences in input reference weights for children of given ages.  
Ghandi et al (2014) calculated a paediatric reference volume based on body surface area (BSA), 
relative to the adult volume of 250 mL and adult BSA of 1.73 m2. The values presented in Table 1 are 
based on average weight and BSA reported in the BNF-C (Committee.). 
Data from International Commission on Radiological Protection (ICRP) (Valentin, 2002) provided 
intestinal dimensions for a wide range of age groups; when correlated to height, weight and body 
surface area of children the small intestinal surface area reported correlated best to body surface 
area in paediatric populations, height consistently overestimated and weight consistently 
underestimated paediatric intestinal surface area (Batchelor and Marriott, 2012). Therefore the use 
of body surface area to calculate gastric volumes may be appropriate, although this results in far 
higher values than those used when calculating according to weight. The data presented by 
Crawford et al (1990) includes paediatric data on gastric volumes and therefore is currently the most 
appropriate source for extrapolation. 
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The information from these papers was used to inform the response options within the 
questionnaire; particularly the lower limits of the solubility volume and dissolution volumes that 
could be selected for the age-range of interest. 
Five additional publications made reference to paediatric biopharmaceutics within the article title, 
abstract or keywords however they did not refer to a pBCS ((Batchelor et al., 2014; Debotton and 
Dahan, 2014; Giacoia et al., 2012; Purohit, 2012)).  
3.2. Survey results 
The survey questions can be seen in appendix A. 
 
3.2.1 Participant demographics 
Sixty individuals completed the survey. It was not possible to calculate a response rate due to the 
opt-in dissemination pathway used to promote the questionnaire. The distribution of the types of 
institution where the participants are employed is shown in Figure 1. It was important that the 
survey was completed by the relevant range of individuals encompassing those in industry, 
regulatory positions and academia. 
 
A large 
pharmaceutical 
company: 31
A small or 
medium sized 
pharmaceutical 
company: 8
A contract 
research 
organisation: 3
A University (or 
other academic 
institution): 13
A regulatory 
agency: 4
Other (Indepen
dent 
consultant): 1
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Figure 1. Demographics of survey participants  
It was important in interpreting the resulting data, that those participating had the relevant 
expertise to ensure that the output is informed by experts in the area. Questions about experience 
working in paediatric medicines and paediatric biopharmaceutics were used to identify the level of 
expertise of those completing the survey 27 % had greater than 5 years’ experience in both 
paediatric medicines and biopharmaceutics. The relatively recent experience of those participating is 
likely to be a consequence of the area of paediatric formulation and biopharmaceutics being 
relatively new having grown since the regulations requiring a paediatric product were introduced the 
past ten years (Committee for Medicinal Products for Human Use (CHMP), 2006; EMA, 2011). 
Subsequent analysis confirmed that the views of those with greater experience were similar to the 
overall views; there were insufficient numbers of highly experienced individuals to allow for 
statistical comparative analysis. 
3.2.2  General findings on the need for a pBCS 
The majority of respondents agreed that a pBCS was needed. The need was considered to be higher 
for younger patients as shown in figure 2. 
 
Figure 2. Percentage of respondents that agree a pBCS is required for the range of age groups. 
0
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90
Newborn (0-27
days):
Infants (28
days-24
months):
Pre-school
children (2-5
years):
School age
children (6-11
years):
Adolescents
(12-18 years):
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In cases where participants did not consider that a pBCS was required it was typically as they did not 
see the value of a pBCS and felt that alternative tools, specifically physiological based 
pharmacokinetic modelling was superior to the crude nature of a pBCS. The reduced need for a pBCS 
in older age groups was typically related to the perception that older children are more like adults in 
terms of gastro-intestinal physiology and therefore the existing adult BCS would be valid in these 
populations. Three participants commented that solid dosage forms are infrequently used in the 
youngest populations and therefore the relevance of a pBCS would be limited. Although solid dosage 
forms are less common than liquids for children’s medicines there is interest in the use of solid 
dosage forms other than conventional tablets in children including: mini-tablets; granules; sprinkles; 
chewable and orally dispersible tablets (Liu et al., 2014). The data presented suggests that further 
work is required to develop a pBCS for children the need was greater in younger populations with 
>75 agreement (which meets typical consensus levels used in Delphi approaches (Diamond et al., 
2014)) in children up to 5 years of age and high agreement for children aged 6-11 years of age. There 
was general agreement that adolescents are similar to adults and therefore can follow the existing 
BCS. 
The survey asked a question about why a pBCS would be useful and asked participants to rank their 
level of concern about the lack of a pBCS against three reasons: inefficient drug development 
process; drug efficacy and child safety. The results are shown in figure 3. 
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Figure 3. Percentage values of participant levels of concern about the lack of a pBCS (black bars 
represent concern with regard to an inefficient drug development process; grey bars drug efficacy 
and striped bars child safety). 
Many respondents commented that the drug efficacy and safety would be measured directly in 
clinical trials and that their concerns were not associated directly with a lack of pBCS. It was also 
noted that two respondents stated that is was a lack of understanding of paediatric 
biopharmaceutics rather than the lack of pBCS that caused them greatest concern. 
In terms of those involved in developing a pBCS the respondents reached consensus, in that >90% 
agreed that regulators, academic and industrial pharmaceutical scientists should be involved. Only 
65% of participants felt that healthcare professionals should be involved in the development of a 
pBCS. In general comments that related to the need for multidisciplinary teams highlighted the 
belief that data on the relevant parameters is scattered and needs to be consolidated and the need 
to engage regulatory agencies throughout the process. 
 
3.2.3 Criteria to classify a drug as highly soluble in a pBCS 
0 10 20 30 40 50 60
Not at all concerned:
A little concerned:
Moderately concerned:
Very concerned:
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Survey participants were asked to state what volume they felt was most appropriate as a criteria to 
classify a drug as highly soluble for a range of paediatric age ranges. The typical volume proposed for 
solubility increased with age as shown in figure 4.  
 
Figure 4. Percentage of respondents who selected the paediatric reference volumes in which the 
highest dose or dose unit should be soluble to classify a drug as highly soluble within a pBCS. (Black 
line = neonates; grey line = infants; dashed line = children aged 2-5 years; dotted line = children aged 
6-11 years and the dot-dash line is adolescents (12-18 years)). 
The paediatric reference volumes in which the highest dose or dose unit should be soluble to classify 
a drug as highly soluble within a pBCS showed reasonable agreement between the participants of 
the survey although consensus, in typical Delphi terminology, was not obtained (<75%). 
Comments relating to reference volumes highlighted that there was insufficient evidence to propose 
or agree with those values suggested, some respondents commented that the two age groups for 
children were still very large and that further subdivisions may be useful. Comments also highlighted 
0
10
20
30
40
50
60
<25mL: 25-50mL: 50-100mL: 100-150mL:150-200mL:200-250mL:250mL - the
same as the
adult BCS:
%
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e
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o
n
d
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that it was the volume of liquid the child was likely to take that should be used to guide this value 
and this should be the focus of further research.  Typically information with in children’s medicines 
(as per the BNFc) state that the product should be consumed with half a glass of water (Truvada ® 
tablets; Rufinamide tablets) or a full glass of water (FasTab®; Elvanse®; Risedronate sodium tablets; 
Etravine tablets; alendronic acid tablets); a full glass means at least 150mL (Committee.). A small 
study conducted reported that mean values of liquids reported to be consumed with tablets were 
82mL for 14-15 year olds and 109mL for 9-10 year olds (Batchelor and Marriott, 2013). 
The survey results did not match any of the previously reported literature values in determining the 
volume for a highly soluble drug. The fixed value of 25mL by Abdel Rahman et al (2012) (Abdel-
Rahman et al., 2012) was reasonably similar to the most popular values for newborns and infants yet 
this was much lower that the values proposed for all older age groups. Using body weight linked to 
fasted gastric volumes as a ratio to propose relevant volumes for the pBCS ((Batchelor, 2014; 
Shawahna, 2016)) gave values that were within those suggested by the survey participants for age 
groups up to 6 years; above 6 years this estimation gave lower volumes than those suggested within 
the survey. Ghandi et al (2014) related volume to body surface area; this gave a better fit to the 
survey data in children over 6 years. Consensus was not achieved for volumes relevant to use in 
paediatric populations, this finding highlights the need for additional research in this area to 
determine both the actual relevant volumes present within the intestinal tract of children as well as 
additional details on the typical volume of liquid taken with medication.  
 
3.2.4 Criteria to classify a drug as highly permeable in a pBCS 
Highly permeable drug classification within the BCS states that drugs where greater than 90% is 
absorbed are classified as highly permeable (Amidon et al., 1995); in terms of paediatrics and 
classification for a pBCS the survey asked whether this classification should remain the same or 
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whether the 90% should be raised or lowered. The most popular selections for each age group are 
shown in table 2. 
 Frequency of response (%) 
Age > 90% absorbed - 
the same value 
as the adult BCS 
A higher % absorbed 
compared to adults 
A lower% absorbed 
compared to adults 
Other 
Newborn 57 9 26 8 
Infant 60 11 23 6 
Child (2-5 
years) 
66 11 16 7 
Child (6-11 
years) 
*79 4 12 5 
Adolescent 
(12-18 years) 
*90 0 7 3 
Table 2. Frequency of responses selected for the classification of a drug as highly permeable 
reported by age category. *Represents answers where consensus was reached (>75% of participants 
agreed). 
The results highlighted that as the age of the child increased the confidence in similarity to adult 
absorption increased with consensus on absorption criteria for older children and adolescents being 
reached (as equivalent to adult values). There was more variability in the younger age groups; many 
comments referred to the conservative nature of the existing 90% criteria and proposed that lower 
values (down to 80%) are reasonable; many others commented on the existing methodology to 
assess permeability and the limitations of these techniques. More recent draft guidance from the 
FDA has reduced high permeability criteria to greater than 85% which reflects the responses found 
within this survey (FDA, May 2015). It was surprising that some participants suggested an even more 
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conservative approach in classification of a highly permeable drug with absorption values even 
higher than 90%, there was only one comment provided to justify this which related to the overall 
permeability and the risk of faster transit in paediatric populations requiring the need for a more 
conservative estimate of permeability and the impact on clinical performance. Participants were 
provided with an option to suggest alternative criteria or provide comments which are listed as 
“other” in Table 2. Typical comments included suggestion of values of 80% (2 responses) as the 
clinical impact of permeability measurements is unknown and the existing value in adults was 
considered by participants to be overly conservative. Another comment left as “other” was that this 
should be calculated based on the drug in question and the clinical risk associated with that 
compound. 
3.2.5 Criteria to classify a drug product as rapidly dissolving in a pBCS 
An immediate release drug product is considered rapidly dissolving when 85% or more of the 
labelled amount of the drug substance dissolves within 30 minutes (a very rapidly dissolving product 
will need to do the same within 15 minutes, within a volume of 900mL or less at a pH range from 1 
to 6.8 (EMA, 2010; FDA, 1995). The criteria for volume of media, timeframe for 85% dissolution and 
pH range for a paediatric population were surveyed and the most popular responses are recorded in 
table 3.  
Age Volume (mL) Time (minutes) pH range (1-6.8) 
Newborn <250  15 mins As per adult 
Infant <250  15 mins As per adult 
Child (2-5 years) 250-500  15 mins *As per adult 
Child (6-11 years) 500-900  *15 mins *As per adult 
Adolescent (12-18 years) 900  *15 mins *As per adult 
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Table 3. Most frequent responses selected for the most appropriate dissolution conditions for 
paediatric products. *Represents answers where consensus was reached (>75% of participants 
agreed). 
Many comments on dissolution referred to the lack of biorelevance of the test for the adult 
population and therefore the limited value in a direct translation into paediatrics(EMA, 2010; FDA, 
2000). The recent draft FDA guidelines propose reducing the volume from 900mL to 500mL (FDA, 
May 2015) which is aligned to many comments made within the survey. There were several 
comments highlighting the lack of reliable data on anatomy and physiology of the paediatric 
intestine which made this question difficult for many people to answer. The full pH range was also 
questioned by some participants as the gastric pH in the youngest population is reported to be 
higher than that in adults; this was reflected in responses where 25% of respondents felt that the pH 
range for newborns and infants can run from 4.5 to 6.8 rather than starting at a lower pH value. 
3.2.6 Proposed areas within paediatric biopharmaceutics for further research 
The survey participants were asked to list up to three priorities for research in paediatric 
biopharmaceutics as it was recognised that this is an under-researched area and there are many 
knowledge gaps. The resulting answers were themed and then prioritised according to the frequency 
with which each suggestion was made; the results are presented in table 4. 
Suggestion Frequency 
Better characterize physiology and anatomy of the GI tract in paediatric patients 25 
Characterize age-specific changes in drug permeation across the intestinal 
membrane 
16 
Development of biorelevant media that better reflect the composition and pH of GI 
fluids in paediatric patients  
11 
Development of biorelevant dissolution tests 11 
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Validation of PBPK in silico models 10 
Understand bridging from adult to paediatric formulations 7 
Understand the food effect 3 
Measure minimum and maximum of drinking volumes 1 
Understand which animal models can be used as models for paediatric intestinal 
tract 
1 
 Table 4. Prioritised proposed areas for research in paediatric biopharmaceutics 
Previously literature reports have prioritised paediatric information of interest including 
gastrointestinal volume and pH, enzyme differentiation and transporter maturation, particularly 
identifying information related to carrier-mediated drugs (Abdel-Rahman et al., 2012; Batchelor et 
al., 2013; Gandhi et al., 2014); this survey of experts provides end-user input into future areas of 
research and it is important to match academic aspirations with the application of their findings.  
 
Conclusions   
This survey confirmed the desire for a pBCS. The survey approach allowed access to those currently 
working in the area of paediatric biopharmaceutics and exposed the relatively new knowledge base 
within this groups as there were only 27% with more than 5 years’ experience in the field. However, 
reaching 60 individuals was considered by the authors to be a representative proportion. It would be 
interesting to repeat this survey in the future when there are more experienced individuals working 
in paediatric biopharmaceutics to demonstrate whether there is a change in thinking as more 
knowledge becomes available. The results also showed discrepancies in pBCS criteria proposed 
within the literature and current thinking of those working in the area; this may be a reflection of 
the relatively recent literature and the lack of a definitive evidence base.  Although consensus was 
not reached in many questions the data presented here highlights the gaps in current knowledge 
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and provides indications of the most appropriate methodology to use in measuring the in vitro 
performance of paediatric medicines. The proposed criteria limits are prudent and based on 
incomplete knowledge therefore additional research is required to generate sufficient, robust 
evidence to underpin a pBCS. However, biowaivers to justify formulation switches for BCS I and III 
drugs where the formulation switch is to a paediatric product need to be undertaken with caution 
due to the dose number adjustment in switching from an adult to a child as well as the lack of 
knowledge in permeability differences. A pBCS would enable a more reliable system on which to 
justify biowaivers for paediatric populations once appropriate boundary criteria have been defined.  
The BCS is known to be prudent therefore it was not surprising that proposed criteria for paediatric 
populations were conservative. This may also be influenced by the greater perception of risk of 
inequivalence in vulnerable paediatric populations. 
It is recognised by the authors, and also the survey respondents, that BCS criteria are frequently 
used during drug development to risk assess decisions; in developing paediatric products a pBCS 
would help in this process. Specific areas were pBCS classifications would be useful include:  
• Early strategic planning of formulation design (specifically dose:solubility ratio); this can 
influence formulation design strategy (and subsequent resource)  and dictate whether an enabled 
formulation is required 
• Determining target limits for dissolution using biopredictive methodology: biopredictive 
rather than biorelevant methods are specifically sought due to the absence of an IVIVC in most cases 
for paediatric products. A biopredictive dissolution method would allow better understanding of the 
critical quality attributes of a paediatric solid dosage form to support QbD risk assessment.  
• Risk assessing inequivalence in paediatric populations compared to adults to enable root 
cause analysis on inequivalence to understand whether the differences observed are related to the 
formulation or the patient anatomy/physiology.  
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 The limitations of a pBCS were highlighted as this is recognised to be a crude estimation of 
product performance yet as outlined above is of value during the development of paediatric 
medicines. A great emphasis was placed on developing age-appropriate biorelevant tools to better 
predict the in vivo performance of paediatric medicines. PBPK is a growing area and the need for a 
pBCS may be superseded by the development of validated models that use the understanding of 
pBCS inputs to better predict in vivo absorption of medicines in children. The same evidence and 
knowledge is required to further develop both parameters for a pBCS and validated PBPK models so 
these tools are likely to be developed in parallel as the evidence base increases. Current paediatric 
medicines development work involves the use of preclinical animal models as well as a range of in 
vitro and in silico tools; additional research is required to understand the relative benefits and 
limitations of each method and its value in predicting clinical performance in paediatric populations. 
Dissemination of these results is critical to promote further research and discussion in this area. 
Furthermore, competent authorities should use this information to inform future guidelines. 
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